Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Tongue Neoplasms 1Stomatitis 1Somatostatinoma 1Radiation Injuries 1Prostatic Neoplasms 1Paraganglioma 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Mouth Neoplasms 1Mediastinal Neoplasms 1Laryngeal Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gliosarcoma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Adenoma, Islet Cell 1

Interventions

Octreotide 4Leucovorin 3Trastuzumab 2Temozolomide 2Oxaliplatin 2Fluorouracil 2Capecitabine 2Bevacizumab 2veliparib 1vatalanib 1tipifarnib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Salts 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Floxuridine 1Fentanyl 1Everolimus 1Disulfides 1Biological Therapy 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vipoma × Salts × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡